Anaphylaxis

อ. พญ. ดารา ไม้เรียง


Objective


- Diagnosis
- Differential diagnosis
- Management
- Advice

Terminology

Severe, rapid in onset, potentially life-threatening systemic hypersensitivity reaction

Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. 2014





Organ involvement


- Skin-mucosal tissue: urticaria, flush, angioedema
- Respiratory: dyspnea, wheeze, bronchospasm, stridor, hypoxemia, cough
- Gastrointestinal: crampy abdominal pain, vomiting, diarrhea
- Cardiovascular: reduced blood pressure, end-organ dysfunction; hypotonia, syncope, incontinence


Signs and symptoms; frequency of occurrence


Signs/Symptoms	Percentage of Cases
Cutaneous	>90
Urticaria and angioedema	85-90
Flush	45-55
Pruritus without rash	2-5
Respiratory	40-60
Dyspnea, wheeze	45-50
Upper airway angioedema	50-60
Rhinitis	15-20
Dizziness, Syncope, Hypotonsion	30-35

Do not rely on hypotension or skin lesion!


J Allergy Clin Immunol 2010;126:477-80 (based on compilation of 1784 patients review)








Biphasic anaphylaxis



Newly generated mediators

Biphasic anaphylaxis



Prostaglandin Leukotriene TNF-a Chemokine

6-8 hours later (15-20%)

Mast cell and basophil mediators

Mediators	Pathophysiologic Activity	Clinical Correlates
Histamine and products of arachidonic acid metabolism (leukotrienes, thromboxane, prostaglandins, platelet- activating factor)	Smooth muscle spasm, mucus secretion, vasodilation, increased vascular permeability, activation of nociceptive neurons, platelet adherence, eosinophil activation, eosinophil chemotaxis	Wheeze, urticaria, angioedema, flush, itch, diarrhea, abdominal pain, hypotension, rhinorrhea, bronchorrhea
Neutral proteases: tryptase, chymase, carboxypeptidase, cathepsin G	Cleavage of complement components, chemoattractants for eosinophils and neutrophils, further activation and degranulation of mast cells, cleavage of neuropeptides, conversion of angiotensin I to angiotensin II	May recruit complement by cleaving C3; may ameliorate symptoms by invoking hypertensive response through angiotensin I-II conversion and by inactivating neuropeptides, although angiotensin II also may cause deleterious coronary artery vasoconstriction. Also, proteases can magnify response because of further mast cell activation.
Proteoglycans: heparin, chondroitin sulfate	Anticoagulation, inhibition of complement, phospholipase A ₂ binding, chemoattractant for eosinophils, cytokine inhibition, kinin pathway activation	Can prevent intravascular coagulation and recruitment of complement. Can recruit kinins, increasing severity of reaction.
Chemoattractants: chemokines, eosinophil chemotactic factors	Summons cells to site	May be partly responsible for recrudescence of symptoms in late phase reaction or extension and protraction of reaction
Tumor necrosis factor a activates nuclear factor-кВ	Produces platelet-activating factor (PAF)	Vascular permeability and vasodilation; PAF synthesized and released late, involved in late phase reactions

Summary: effect of mediators

Pathophysiology	Clinical
smooth muscle spasm	
- Bronchi	Wheeze
- Coronary arteries	Myocardial ischemia
- GI tract	Nausea, vomiting, diarrhea
Increased vascular	Flush, urticaria and
permeability and vasodilatation	angioedema, hypotension
Myocardial depression	Hypotension, poor perfusion
Increased grandular secretion	Bronchorrhea, rhinorhea

Differential diagnosis

Vasomotor reaction	Excessive histamine
 Flush syndromes Medullary carcinoma thyroid Autonomic epilepsy 	 Systemic mastocytosis Urticaria pigmentosa Basophilic leukemia Hydatid cyst
Restaurant syndrome	Non organic disease
 Monosodium glutamate Sulfites Scombroidosis 	 Panic attacks Munchausen stridor Vocal cord dysfunction
Other form of shock	Miscellaneous
Hemorrhagic Cardiogenic Endotoxic	 Hereditary angioedema Urticarial vasculitis Pheochromocytoma Hyper-IgE, urticaria syndrome Neurologic (seizure, stroke) Red man syndrome Capillary leak syndrome

Common disorder	Cinical presentation	Anaphylaxis
Urticaria/angioedema	Limited to skin and	Involvement of one or
	subcutaneous tissues	more body system
Asthma exacerbation	Isolated respiratory	Onset within minutes or a
	symptoms	few hours after exposure
		to a likely trigger
Vasovagal syncope	Diaphoresis, nausea,	Flushing, itching,
	vomiting, bradycardia,	urticaria, angioedema,
	pallor	respiratory compromised,
		tachycardia
Other forms of shock	More gradual, onset	Sudden onset

Ongoing symptoms that are consistent with anaphylaxis, the patient should receive adrenaline promptly!


Laboratory findings


- Tryptase: 60 min-4 hours
- Plasma and urine histamine: 5-60 mins
- Platelet activating factor level: correlate with severity
- Allergologic work up; Skin test, specific IgE, No definite biomarker. Diagnosis rely on clinical presentation!

Emergency management

Adrenaline

- Drug of choice for anaphylaxis
- Pharmacologic actions address the pathophysiologic changes
- Decreases mediator release from mast cells
- The only medication that prevents or reverses obstruction to airflow and cardiovascular collapse






Additional pharmacologic effects: at β ,-receptor: \uparrow heart rate; \uparrow cardiac contraction force

BP = blood pressure; BD=bronchodilation

Adrenaline absorption : intramuscular VS subcutaneous



Intravenous adrenaline


- severe hypotension, cardiovascular collapse, no response to repeated IM administration (poor absorption)
- Continuous infusion is superior to IV bolus
- IV bolus injections in cardiac arrest
- IV adrenaline in patients with adequate circulation may cause life-threatening hypertension, myocardial ischemia, arrhythmias
- should be monitored with continuous ECG, pulse oximetry, and frequent noninvasive blood pressures

Intravenous fluid

- Massive fluid shifts due to increased vascular permeability combined with the effects of vasodilation
- Initiated in orthostasis, hypotension
- Normal saline 10-20 mL per kilogram in 5-10 minutes

Positioning

- Respiratory distress \rightarrow sitting up
- Circulatory instability \rightarrow lying on back with the lower extremities elevated
- Unconscious \rightarrow recovery position
- Avoid sudden abrupt change to a more upright posture



Oxygen

- High-flow oxygen should be administered by face mask
- Patients with hypotension or tachypnea
- Improve acidosis→ improve adrenaline absorption

Adjunctive treatment

H1 antihistamines

- Relieving itching and hives
- Do not relieve airway obstruction, gastrointestinal symptoms, shock
- Do not inhibit mediator release from mast cells

H2 antihistamines

 May provide some additional benefit of vasodilatation; decreased headache (one study in mild reaction)

Not drug of choice!

Ann Emerg Med 2000;36: 462-8

Adjunctive treatment


Inhaled β -adrenergic agonists


- Treatment of bronchospasm not responsive to adrenaline
- Do not prevent or relieve mucosal edema in the upper airway

Glucocorticoids

- Onset of action takes 4-6 hours
- Do not relieve the initial symptoms
- Prevent protracted and biphasic anaphylaxis (no clear evidence)
- Stopped after three days without a taper


Ann Allergy Asthma Immunol 2005;95: 217-28






No response in 5-10 mins \rightarrow Reapeat Adrenaline i.m. and the above steps

Modified from Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. 2014





Dosage and route of administration

Drug	Dose/Route	Comment		
Adrenaline (1:1,000)	(max 0.3ma) i m	- Initial drug of choice - repeat every 5-15 minutes		
ANTIHISTAMINES				
	1-2 mg/kg/dose (max 50 mg)	Second line treatment		
Chlopheniramine	0.25 mg/kg i.v	Dose for anaphylaxis		
Ranitidine	1 mg/kg i.v (max 50 mg)			

แนวทางเวชปฏิบัติสำหรับการดูแลผู้ป่วยที่มีอาการแพ้ชนิดรุนแรง พ.ศ.2560

		i
Drug	Dose/Route	Comment
CORTICOSTEROIDS		
Hydrocortisone	4-8 mg /kg i.v (max 100 mg)	Exact dose not established
Methylprednisolone	1-2 mg/kg/dose i.v (max 50 mg)	Adapted from asthma treatment
Prednisolone	1-2 mg/kg/day p.o. (max 40 mg)	For mild episode
DRUGS FOR BRONCH	OSPASM	
Aerosolized β-agonist	Solution : 0.03 mg/kg/dose (max 5 mg) Nebule: (2.5 mg/2.5ml) 1-2 nebules	 Dose = asthma Bronchospasm not responding to adrenaline

แนวทางเวซปฏิบัติสำหรับการดูแลผู้ป่วยที่มีอาการแพ้ชนิดรุนแรง พ.ศ.2560

Common pitfalls

- Reluctant to diagnose anaphylaxis in the absence of shock/skin lesions
- Anaphylaxis in a known asthmatic may be mistaken for an asthma exacerbation
- Patients may not recognize the symptoms as a serious allergic reaction
- Reluctant to use adrenaline \rightarrow fatality

Observation period

- No consensus or RCT, at least 4-8hours
- Biphasic episodes
- Longer observation period (8 to 24 hours) esp in
 - Severe/ protracted anaphylaxis; hypotension or collapse
 - Underlying asthma, cardiovascular, using B-blocker
 - Ingested antigen with possibility of continued absorption
 - Previous history of biphasic response

Discharge planning

Prednisolone

1-2 mkd/day for 72 hours

Counseling

- They have anaphylaxis which is a life-threatening condition
- Symptoms may recur up to three days
- Risk for repeat episodes

Allergen identification and avoidance

- Avoidance
- Immunotherapy
- Desensitization
- Premedication

Discharge planning

Acute managent

- Rapid recognition of symptoms
- Administer adrenaline
- Emergency medical service

Adrenaline for emergencies

- Provide the patient with a self-injectable adrenaline
- Importance of carrying the adrenaline at all times
- Educate family members

Epipen autoinjector



EpiPen[®] (adrenaline) 0.3 mg
 EpiPen Jr[®] (adrenaline) 0.15 mg

Adrenaline kit

-				ky
	S S	Safe kit	ไรคภูมิแพ้ คณะแพทยศาสตร์โรงพยาบาลรามาชิบดี โร	15 022011760
	11-		อายุ :ปี โทร	
11A	12 T	สิ่งที่แพ้ :	วันหมดอายุ	
12	L	MAGE IN THAILAND		

มาการของภาวะแพ้อย่างรุนแรง มีดังต่อไปนี้ ปาวา คันวิมอิปาก และางวิช ลั้นบวม	แผนการปฏิบัติเมื่อเกิดภาวะแพ้อย่างรุนแรง	
ต่อหลอย ดับ จากแนนไม่ม้าคาด เรื่องแหบ อิวหนัง ดับ จีนองพิช แตง บาท ทางเสียอาหาร อาเรียน ถ่างแหว ปาตท้อง ปอด" นายโจติดรัก โอ นายใจมีเสียงรื่ เว็บโจ" จังงงานา เวียนสีของ เรียชีวิต อาจงออกการแหล่านี้เสียงส่วนหนึ่งเหานั้น ความรูนและราชเอกการกามารถปลียนและได้อยป้างราดเร็ก "บาจจากการกำไปเปิดต้นเดาะอยถึงแปรีวลได้ รับปฏิบัติการจรับ	สิ่งที่ด้องหัา 1 ลัดยา โอเกออุกศกด ที่ดันขาด้านบอก CC 2 เกลิ้นๆรนาดยาไห้ทาง 3 คิดต่อสถานพยาบาลที่ไกล์ที่ลูด หรือ โทร 4 ถูกเป็นติดต่อ 1โทร 2โทร	
	Hantindanian Industry Industry 3	21 to
16.		
L. L. B. Walnut and	tentententent menetententententent	





When to refer

- Allergen identification
- Recurrent
- Severe reaction
- Immunotherapy; insect

Take home message

Either shock or skin/mucosal lesion are not required for the diagnosis

Adrenaline is the first line drug